Compare Ascendis Pharma A/S (ASND) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Enbridge Inc — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Enbridge Inc trades at $51.75 (market cap $112.62B). The key difference: Enbridge Inc is far larger — about 6.8× Ascendis Pharma A/S's market cap, and Enbridge Inc pays a 5.34% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ENB | |
|---|---|---|
Market Cap | $16.67B | $112.62B |
Sector | Health | Energy |
52-Week High | $277.18 | $58.04 |
52-Week Low | $189.74 | $45.23 |
Enterprise Value | $17.04B | $196.53B |
Dividend Yield | — | 5.34% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
